甲癣市场规模、份额和成长分析（按类型、治疗方法和地区划分）—2026-2033年产业预测

预计到 2024 年，全球甲癣市场规模将达到 55.4 亿美元，到 2025 年将达到 57.9 亿美元，到 2033 年将达到 82.3 亿美元，在预测期（2026-2033 年）内，复合年增长率为 4.5%。

全球甲癣市场涵盖了致力于诊断、治疗和管理真菌性甲感染疾病的製药和医疗保健领域。这种常见疾病会导致指甲变色、增厚和脆弱，进而可能引起不适和併发症。市场成长的主要驱动因素包括人们对指甲健康的日益重视、与老龄化、糖尿病和免疫抑制等因素相关的甲癣发病率上升，以及诊断和治疗方法的进步。该市场提供多种治疗方案，包括外用和口服抗真菌药物、指甲油以及清创和雷射治疗设备。相关人员正专注于研究、产品发布和策略合作。对创新治疗方法的需求不断增长，正在推动北美、欧洲和亚太地区的市场扩张。

全球甲癣市场驱动因素

推动全球甲癣市场发展的关键因素是各种风险因素的日益增多，例如糖尿病、老化、免疫系统减弱和指甲外伤。这些因素会增加真菌感染疾病的风险，导致需要进行甲癣诊断和治疗的患者群体不断扩大。随着这些风险因素的日益普遍，对有效治疗方法的需求持续增长，推动了市场的发展。此外，人们对真菌性感染疾病的认识不断提高，也促使更多患者寻求医疗干预和预防措施。

限制全球甲癣市场发展的因素

全球甲癣市场的主要阻碍因素是现有治疗方法的潜在副作用和限制。虽然口服抗真菌药物已被证实有效，但它们可能引起全身性副作用，并且需要密切监测以确保患者安全。此外，局部治疗在处理严重或深部感染疾病时往往效果不佳，这给成功治疗设置了障碍。这些挑战不仅阻碍了市场扩张，也使为灰指甲患者提供安全有效的治疗方案变得更加复杂，最终影响患者照护和治疗的连续性。

全球甲癣治疗市场趋势

全球甲癣市场正呈现出显着的发展趋势，这主要得益于市场对创新且易于使用的治疗方法的需求不断增长。患者和医疗服务提供者都在寻求能够提高疗效、缩短疗程并增强患者治疗依从性的疗法。为此，业内相关人员正积极投资研发，推出包括先进外用製剂和专用甲油在内的创新配方。此外，雷射疗法等先进技术的探索也标誌着治疗方向正朝着更精准有效的方向发展，这凸显了业界致力于满足患者需求并改善真菌性感染疾病治疗效果的决心。

目录

介绍

• 调查目标
• 调查范围
• 定义

调查方法

• 资讯收集
• 二手资料和一手资料方法
• 市场规模预测
• 市场假设与限制

执行摘要

• 全球市场展望
• 供需趋势分析
• 细分市场机会分析

市场动态与展望

• 市场规模
• 市场动态
  • 驱动因素和机会
  • 限制与挑战
• 波特分析

关键市场考察

• 关键成功因素
• 竞争程度
• 关键投资机会
• 市场生态系统
• 市场吸引力指数（2025）
• PESTEL 分析
• 总体经济指标
• 价值链分析
• 定价分析

全球甲癣市场规模（按类型及复合年增长率划分）（2026-2033 年）

• 远端甲下甲癣
• 白色浅层甲癣
• 近端甲下甲癣
• 其他的

全球甲癣市场规模（按治疗方法和复合年增长率划分）（2026-2033 年）

• 口服
• 外用药物
• 其他的

全球甲癣市场规模及复合年增长率（2026-2033）

• 北美洲
  • 美国
  • 加拿大
• 欧洲
  • 德国
  • 西班牙
  • 法国
  • 英国
  • 义大利
  • 其他欧洲地区
• 亚太地区
  • 中国
  • 印度
  • 日本
  • 韩国
  • 亚太其他地区
• 拉丁美洲
  • 巴西
  • 其他拉丁美洲地区
• 中东和非洲
  • 海湾合作委员会国家
  • 南非
  • 其他中东和非洲地区

竞争资讯

• 前五大公司对比
• 主要企业的市场定位（2025 年）
• 主要市场参与者所采取的策略
• 近期市场趋势
• 公司市占率分析（2025 年）
• 主要企业公司简介
  • 公司详情
  • 产品系列分析
  • 依业务板块进行公司股票分析
  • 2023-2025年营收年比比较

主要企业简介

• Bausch Health Companies Inc.（Canada）
• GSK plc（UK）
• Abbott（US）
• Pfizer Inc.（US）
• Bayer AG（Germany）
• Teva Pharmaceutical Industries Ltd.（Israel）
• Cipla Inc.（India）
• Merck & Co., Inc.（US）
• Novartis AG（Switzerland）
• Sun Pharmaceutical Industries Ltd.（India）
• Sanofi（France）
• Johnson & Johnson（US）
• Eli Lilly and Company（US）
• Mylan NV（US）
• Galderma SA（Switzerland）
• Valeant Pharmaceuticals International, Inc.（Canada）
• Sandoz International GmbH（Germany）
• Lupin Limited（India）
• Dr. Reddy's Laboratories Ltd.（India）
• Aurobindo Pharma Limited（India）

结论与建议

Global Onychomycosis Market size was valued at USD 5.54 Billion in 2024 and is poised to grow from USD 5.79 Billion in 2025 to USD 8.23 Billion by 2033, growing at a CAGR of 4.5% during the forecast period (2026-2033).

The global onychomycosis market encompasses the pharmaceutical and healthcare sectors dedicated to the diagnosis, treatment, and management of nail fungal infections. This common condition, which leads to nail discoloration, thickening, and brittleness, can result in discomfort and complications. Key drivers of market growth include heightened awareness of nail health, the rising incidence of onychomycosis linked to factors such as aging, diabetes, and immune suppression, alongside advancements in diagnostics and therapies. The market features a variety of treatment options, including topical and oral antifungals, nail lacquers, and devices for debridement and laser therapy. Major stakeholders engage in research, product launches, and strategic partnerships, while regions like North America, Europe, and Asia Pacific significantly contribute to market expansion as innovative treatment demand grows.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Onychomycosis market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Onychomycosis Market Segments Analysis

Global Onychomycosis Market is segmented by Type, Treatment and region. Based on Type, the market is segmented into Distal Subungual Onychomycosis, White Superficial Onychomycosis, Proximal Subungual Onychomycosis and others. Based on Treatment, the market is segmented into Oral, Topical and others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Onychomycosis Market

A significant factor driving the global onychomycosis market is the rising incidence of various risk factors, including diabetes, an aging demographic, compromised immune systems, and instances of nail trauma. These conditions heighten the vulnerability to fungal infections, resulting in an expanding population of patients in need of diagnosis and treatment for onychomycosis. As these risk factors become more prevalent, the demand for effective therapeutic options continues to grow, thus propelling the market forward. The increasing awareness of fungal nail infections also plays a role in elevating the need for medical interventions and preventative measures among affected individuals.

Restraints in the Global Onychomycosis Market

A significant constraint in the Global Onychomycosis market stems from the potential side effects and limitations of existing treatment modalities. While oral antifungal medications are recognized for their effectiveness, they can lead to systemic side effects that necessitate close monitoring to ensure patient safety. Moreover, topical treatments often demonstrate reduced efficacy when addressing severe or deeply rooted infections, creating barriers to successful outcomes. These challenges not only impede market expansion but also complicate the provision of safe and effective treatment alternatives for individuals suffering from onychomycosis, ultimately impacting patient care and treatment adherence.

Market Trends of the Global Onychomycosis Market

The global onychomycosis market is witnessing a significant trend driven by the increasing demand for innovative and user-friendly treatment options. Patients and healthcare providers are seeking therapies that not only enhance efficacy and shorten treatment times but also improve overall adherence to treatment regimens. In response, industry players are actively investing in research and development efforts to introduce groundbreaking formulations, including advanced topical solutions and specialized lacquers. Additionally, the exploration of cutting-edge technologies such as laser therapy indicates a shift towards more precise and effective treatments, underscoring the sector's dedication to addressing patient needs and improving outcomes in combating fungal nail infections.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2025
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis

Global Onychomycosis Market Size by Type & CAGR (2026-2033)

• Market Overview
• Distal Subungual Onychomycosis
• White Superficial Onychomycosis
• Proximal Subungual Onychomycosis
• others

Global Onychomycosis Market Size by Treatment & CAGR (2026-2033)

• Market Overview
• Oral
• Topical
• others

Global Onychomycosis Market Size & CAGR (2026-2033)

• North America (Type, Treatment)
  • US
  • Canada
• Europe (Type, Treatment)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Type, Treatment)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Type, Treatment)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Type, Treatment)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2025
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2025
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

• Bausch Health Companies Inc. (Canada)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• GSK plc (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Abbott (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pfizer Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bayer AG (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Teva Pharmaceutical Industries Ltd. (Israel)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Cipla Inc. (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck & Co., Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novartis AG (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sun Pharmaceutical Industries Ltd. (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sanofi (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Johnson & Johnson (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Eli Lilly and Company (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Mylan N.V. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Galderma S.A. (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Valeant Pharmaceuticals International, Inc. (Canada)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sandoz International GmbH (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Lupin Limited (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Dr. Reddy's Laboratories Ltd. (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Aurobindo Pharma Limited (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations